HRP20040150A2 - Use of bibn4096 u combination with other antimigraine drugs for the treatment of migraine - Google Patents

Use of bibn4096 u combination with other antimigraine drugs for the treatment of migraine Download PDF

Info

Publication number
HRP20040150A2
HRP20040150A2 HR20040150A HRP20040150A HRP20040150A2 HR P20040150 A2 HRP20040150 A2 HR P20040150A2 HR 20040150 A HR20040150 A HR 20040150A HR P20040150 A HRP20040150 A HR P20040150A HR P20040150 A2 HRP20040150 A2 HR P20040150A2
Authority
HR
Croatia
Prior art keywords
physiologically acceptable
acceptable salt
dose
sumatriptan
body weight
Prior art date
Application number
HR20040150A
Other languages
English (en)
Croatian (hr)
Inventor
Henri Doods
Klaus Rudolf
Wolfgang Eberlein
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of HRP20040150A2 publication Critical patent/HRP20040150A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HR20040150A 2001-08-17 2002-08-10 Use of bibn4096 u combination with other antimigraine drugs for the treatment of migraine HRP20040150A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10139410A DE10139410A1 (de) 2001-08-17 2001-08-17 Verwendung von BIBN4096 in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
PCT/EP2002/008993 WO2003015787A1 (en) 2001-08-17 2002-08-10 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine

Publications (1)

Publication Number Publication Date
HRP20040150A2 true HRP20040150A2 (en) 2004-06-30

Family

ID=7695082

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20040150A HRP20040150A2 (en) 2001-08-17 2002-08-10 Use of bibn4096 u combination with other antimigraine drugs for the treatment of migraine

Country Status (22)

Country Link
EP (1) EP1420790B1 (de)
JP (1) JP2005503382A (de)
KR (1) KR20040027892A (de)
CN (1) CN1543347A (de)
AR (1) AR036265A1 (de)
AT (1) ATE304854T1 (de)
BR (1) BR0211970A (de)
CA (1) CA2454083A1 (de)
CO (1) CO5560577A2 (de)
DE (2) DE10139410A1 (de)
EA (1) EA200400253A1 (de)
EC (1) ECSP044979A (de)
ES (1) ES2250733T3 (de)
HR (1) HRP20040150A2 (de)
HU (1) HUP0401484A3 (de)
IL (1) IL159879A0 (de)
MX (1) MXPA04001364A (de)
NO (1) NO20041024D0 (de)
PL (1) PL365482A1 (de)
UY (1) UY27416A1 (de)
WO (1) WO2003015787A1 (de)
ZA (1) ZA200400313B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8465468B1 (en) 2000-06-29 2013-06-18 Becton, Dickinson And Company Intradermal delivery of substances
DE10207026A1 (de) * 2002-02-20 2003-08-28 Boehringer Ingelheim Kg Pulverinhalativum, enthaltend den CGRP-Antagonisten BIBN4096 und Verfahren zu dessen Herstellung
EP1374870A1 (de) * 2002-06-24 2004-01-02 Rita Dobmeyer Arzneimittel zur Behandlung oder Vorbeugung von Migräne
DE10314617A1 (de) * 2003-04-01 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung des Hydrochlorids der Wirkstoffbase 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne
DE10338407A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Inhalationspulver enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin
DE10338403A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverformulierung, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl]-1-piperidinyl]carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyrindinyl)-piperazin, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338402A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknetes, amorphes BIBN 4096, Verfahren zu dessen Herstellung sowie dessen Verwendung als Inhalativum
DE10338399A1 (de) * 2003-08-18 2005-03-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Mikropartikel, enthaltend den CGRP-Antagonisten 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]carbonyl]-D-tyrosyl]-L-Iysyl]-4-(4-pyridinyl)-piperazin, Verfahren zu deren Herstellung sowie deren Verwendung als Inhalaltionspulver
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
CA2563687A1 (en) * 2004-04-20 2005-11-03 Boehringer Ingelheim International Gmbh Use of a cgrp-antagonist combined with a serotonin-reuptake inhibitor in order to treat migraines
EP1744784A2 (de) * 2004-05-11 2007-01-24 Becton, Dickinson and Company Schmerzmittelformulierungen und verfahren zu deren anwendung
DE102004063753A1 (de) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung ausgewählter CGRP-Antagonisten in Kombination mit anderen Arzneistoffen gegen Migräne für die Behandlung von Migräne
RU2313340C1 (ru) * 2006-02-20 2007-12-27 Дмитрий Владимирович Зимин Лекарственное средство, обладающее противомигренозным действием, и способ его изготовления
RU2424803C2 (ru) * 2008-04-07 2011-07-27 Учреждение Российской академии медицинских наук Научно-исследовательский институт фармакологии имени В.В. Закусова РАМН (НИИ фармакологии имени В.В.Закусова РАМН) Фармацевтическая композиция с противомигреневым действием (варианты)
CN102526031A (zh) * 2010-12-27 2012-07-04 湖南九典制药有限公司 一种鼻腔内使用的舒马普坦药物组合物及其制备方法
CN103385876B (zh) * 2012-05-08 2016-01-13 四川滇虹医药开发有限公司 一种夫罗曲坦的药物组合物及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU721035C (en) * 1996-09-10 2004-09-02 Dr. Karl Thomae Gmbh Modified aminoacids, pharmaceuticals containing these compounds and method for their production
DE19937304C2 (de) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Verwendung von CGRP-Antagonisten zur Bekämpfung menopausaler Hitzewallungen

Also Published As

Publication number Publication date
EP1420790A1 (de) 2004-05-26
BR0211970A (pt) 2004-09-21
HUP0401484A2 (hu) 2004-12-28
DE60206289D1 (de) 2006-02-02
IL159879A0 (en) 2004-06-20
CN1543347A (zh) 2004-11-03
EA200400253A1 (ru) 2004-08-26
ATE304854T1 (de) 2005-10-15
HUP0401484A3 (en) 2007-03-28
NO20041024D0 (no) 2004-02-16
ZA200400313B (en) 2004-11-01
CA2454083A1 (en) 2003-02-27
CO5560577A2 (es) 2005-09-30
KR20040027892A (ko) 2004-04-01
AR036265A1 (es) 2004-08-25
MXPA04001364A (es) 2004-05-27
DE60206289T2 (de) 2006-06-08
DE10139410A1 (de) 2003-02-27
WO2003015787A1 (en) 2003-02-27
JP2005503382A (ja) 2005-02-03
ES2250733T3 (es) 2006-04-16
UY27416A1 (es) 2003-03-31
EP1420790B1 (de) 2005-09-21
ECSP044979A (es) 2004-04-28
PL365482A1 (en) 2005-01-10

Similar Documents

Publication Publication Date Title
US20030181462A1 (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
Williamson et al. The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation
US6521609B1 (en) Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
KR100435611B1 (ko) 에피나스틴을포함하는동통치료용약제학적조성물
JP5756250B2 (ja) 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法
US20030022926A1 (en) Method for treating neuropathic pain and pharmaceutical preparation therefor
EP1420790B1 (de) Verwendung von bibn4096 in kombination mit anderen migränemitteln zur behandlung von migräne
KR20080007233A (ko) 두통용 디히드로피리딘 화합물 및 조성물
EP0279114B1 (de) Arzneimittel zur Behandlung oder Vorbeugung des Entzugssyndromes
ES2231243T3 (es) Uso de antagonistas del cgrp e inhibidores de la liberacion de cgrp para combatir sofocos menopausicos.
CN101534830A (zh) 具有止痛活性并因此用于治疗或预防疼痛的吡唑基衍生物
JP2004508311A (ja) 頭痛、片頭痛、悪心及び嘔吐用の医薬組成物
JP2786411B2 (ja) 不安症の治療
TW200815008A (en) Method for enhancing cognitive function
ES2312588T3 (es) Regulacion de la secrecion del jugo pancreatico que comprende un agente de regulacion del receptor del lpa.
US20150023888A1 (en) Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine
US20030008005A1 (en) Sublingual administration of dihydroergotamine for the treatment of migraine
US20040248816A1 (en) Treatment of migraine
JP2008507577A (ja) 中枢神経系の障害を治療するための医薬
Yoneda et al. Serotonin enhances gastric acid response to TRH analogue in dorsal vagal complex through 5-HT2 receptors in rats
JP2006522044A (ja) 偏頭痛の治療のための化合物１−［ｎ２−［３，５−ジブロモ−ｎ−［［４−（３，４−ジヒドロ−２（１ｈ）−オキソキナゾリン−３−イル）−１−ピペリジニル］−カルボニル］−ｄ−チロシル］−ｌ−リシル］−４−（４−ピリジニル）−ピペラジンの塩酸塩とスマトリプタンとの組み合せ使用
JP5078209B2 (ja) 急なベンゾジアゼピン離脱処置のためのシアメマジンの使用
CN100354274C (zh) 神经变性疾病的预防和治疗药物
JP2002523363A (ja) 慢性疲労症候群および／または線維筋痛の処置のためのサブスタンスｐアンタゴニストの使用および慢性疲労症候群の処置のためのｎｋ−１レセプターアンタゴニストの使用
AU2002333393A1 (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
OBST Application withdrawn